Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma

Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the stand...

Descripción completa

Detalles Bibliográficos
Autores: Garcia Guiñón, Antoni, Charry, Paola|||0000-0002-4777-9643, Jimenez, María, Sarra, J., Delgado, I., Segura de la Torre, Laura, Santaliestra, M., Garcia-Pintos, M., Gonzalez, Y., Senin, Alicia|||0000-0001-5075-8731, Motlló Borrella, Cristina, Abella Monreal, Eugenia|||0000-0001-9605-8458, Cabezudo, E., Granell, Miquel|||0000-0002-0366-3673, Sancho, E., Herranz, M.J., Seres, Y., Gironella, Mercedes|||0000-0002-8106-8909, Soler, Juan Alfons, Marti-Tutusaus, J.M., Ben Azaiz, Ran, Fernández de Larrea, Carlos|||0000-0003-4930-9255
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:320624
Acceso en línea:https://ddd.uab.cat/record/320624
https://dx.doi.org/urn:doi:10.1007/s00277-025-06240-1
Access Level:acceso abierto
Palabra clave:Carfilzomib
Lenalidomide and dexamethasone
Real-world
Relapsed/refractory multiple myeloma
Descripción
Sumario:Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planned to include at least 100-150 patients. In total 194 patients were included. Median age was 64 years (range: 40-88) and 56% were male. All patients had received bortezomib. Additionally, 89 patients (46%) had received thalidomide and 29 (15%) lenalidomide. The ORR was 73% (95% CI: 66-79), with 72 patients (37%) having ≥ CR. The ORR was influenced by ISS score, number of previous treatments and exposure to lenalidomide. The median PFS was 26 months and 2-years OS rate 70%. The ISS stage and LDH levels were independent prognostic factors of survival. In conclusion, the KRd scheme led to a good effectiveness comparable safety profile to the phase III clinical trial in patients with RRMM.

Similares en LA Referencia